Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2017-04-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-16-0555PMID 28428442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD79B limits response of diffuse large B cell lymphoma to ibrutinib

  2016cited by this paper
• Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

  2016influential reference
• FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma

  2016influential reference
• Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.

  2015cited by this paper
• The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

  2015cited by this paper
• MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors

  2015cited by this paper
• Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma

  2015cited by this paper
• Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1

  2015cited by this paper
• Combination of ibrutinib with ABT‐199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways

  2015influential reference
• Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

  2015influential reference
• Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma

  2015cited by this paper
• Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

  2015cited by this paper
• Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

  2015cited by this paper
• The BCL2 antagonist ABT‐199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild‐type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells

  2015cited by this paper
• High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

  2014cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• Ibrutinib resistance in chronic lymphocytic leukemia.

  2014cited by this paper
• Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

  2013cited by this paper
• Reprogramming cell death: BCL2 family inhibition in hematological malignancies.

  2013cited by this paper
• Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia.

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).

  2013cited by this paper
• The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.

  2012cited by this paper
• Oncogenically active MYD88 mutations in human lymphoma

  2011cited by this paper
• Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

  2010cited by this paper
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

  2009cited by this paper
• Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

  2009cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• The biology of human lymphoid malignancies revealed by gene expression profiling.

  2005cited by this paper
• Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome.

  2004cited by this paper
• Mechanisms and implications of imatinib resistance mutations in BCR-ABL

  2004influential reference
• A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

  2003cited by this paper
• Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer

  2001cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper

• BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies.

  2025cites this paper
• Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma.

  2025cites this paper
• Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells

  2024cites this paper
• A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma

  2024cites this paper
• The prognostic value of hydroxybutyrate dehydrogenase in diffuse large B cell lymphoma

  2024cites this paper
• Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib

  2024influential citation
• Unleashing the Potential of Ibrutinib-Loaded Nanoparticles for Cancer Treatment—A Comprehensive Review

  2024cites this paper
• Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.

  2024cites this paper
• Zanubrutinib is effective in non-germinal-center B-cell-like diffuse large B-cell lymphoma with mutated CD79B, high TCL1A expression, or over- expressed MYC/BCL-2

  2024influential citation
• Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation.

  2024cites this paper
• Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma

  2023cites this paper
• Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma

  2023cites this paper
• A Combination of CPI-0610 and SAHA Induces Apoptosis through STAT3 and p38 Signalling Pathways in Diffuse Large B-cell Lymphoma Cells.

  2023cites this paper
• Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma.

  2023cites this paper
• Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach

  2022cites this paper
• Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review

  2022cites this paper
• Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.

  2022cites this paper
• CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China

  2022cites this paper
• Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma

  2022cites this paper
• Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression

  2022cites this paper
• Progress in understanding the mechanisms of resistance to BCL-2 inhibitors

  2022cites this paper
• Apatinib enhances chemosensitivity of ABT‐199 in diffuse large B‐cell lymphoma

  2022cites this paper
• Venetoclax in Previously Treated Waldenström Macroglobulinemia

  2021cites this paper
• Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma

  2021cites this paper
• Multiomics Integration Elucidates Metabolic Modulators of Drug Resistance in Lymphoma

  2021cites this paper
• Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma

  2021cites this paper
• Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma

  2021cites this paper
• Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma

  2021cites this paper
• The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

  2021cites this paper
• Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)

  2021cites this paper
• Clinicopathologic and Prognostic Significance of Bruton’s Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma

  2021cites this paper
• Barriers to achieving a cure in lymphoma

  2021cites this paper
• BH3-mimetics: recent developments in cancer therapy

  2021cites this paper
• Inhibitors of Bcl-2 and Bruton’s tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models

  2021cites this paper
• Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.

  2021cites this paper
• A novel BCL-2 inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-P53 inhibitor in Diffuse Large B-Cell Lymphoma.

  2020cites this paper
• Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.

  2020cites this paper
• De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances.

  2020cites this paper
• Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells

  2020cites this paper
• Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.

  2020cites this paper
• Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies

  2020cites this paper
• Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance

  2020cites this paper
• Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas

  2020cites this paper
• Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma

  2020cites this paper
• PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR

  2020cites this paper
• TITLE PAGE Title: Overcoming ibrutinib resistance by targeting phosphatidylinositol-3-kinase signaling in diffuse large B-cell lymphoma

  2019cites this paper
• MYC in Germinal Center‐derived lymphomas: Mechanisms and therapeutic opportunities

  2019cites this paper
• Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma

  2019cites this paper
• Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets

  2019cites this paper
• Transformed Follicular Lymphoma

  2019cites this paper
• Resistance to Bruton’s Tyrosine Kinase Signaling Pathway Targeted Therapies

  2019cites this paper
• Resistance to Targeted Therapies in Lymphomas

  2019cites this paper
• Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.

  2019cites this paper
• Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities

  2019cites this paper
• Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy

  2018cites this paper
• Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.

  2018cites this paper
• Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

  2018cites this paper
• Primary diffuse large B-cell lymphoma in the maxilla

  2018cites this paper
• Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy

  2018cites this paper
• Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma

  2018cites this paper
• Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2

  2018cites this paper